How to read the plasmid map?
ADC评论
October 31, 2022
In the field of biological scientific research, you often come into contact with the little thing called plasmid, and when you find the map of
Month: October 2022
Conjugation technology of ADC
ADC评论
October 31, 2022
The conjugation of Linker-drug (LD) to antibodies is a critical step in the generation of ADCs and the determination of key quality attributes of ADCs
FDA rejects Gilead’s bulevirtide marketing application
ADC评论
October 29, 2022
On October 27, Gilead announced its Q3 financial report and revealed that its marketing application for bulevirtide (trade name: Hepcludex) for the treatment of chronic
Merck drops oncolytic virus therapy Cavatak (V937)
ADC评论
October 29, 2022
On October 27, Merck announced its third-quarter financial report, and its product pipeline no longer includes the oncolytic virus therapy Cavatak (V937) obtained from the
New HIV drug Biktarvy released real-world data, significant safety and efficacy
ADC评论
October 28, 2022
Gilead Sciences recently announced the real-world data (RWD) of the three-in-one compound new drug Biktarvy BICSTaR study at the 30th International Conference on Drug Therapy
ESSA’s mCRPC drug EPI-7386 has positive clinical effects, stock prices soar
ADC评论
October 28, 2022
On October 26, ESSA Pharma announced the latest positive results from the first two cohorts of the company’s lead drug candidate EPI-7386 in combination with
RWD study: Lenvima shows high efficacy in thyroid cancer
ADC评论
October 27, 2022
Eisai recently announced the final results of a real-world data (RWD) study at the 91st American Thyroid Association (ATA) Annual Meeting in 2022. This study
AstraZeneca’s Akt inhibitor successful in phase III study in breast cancer
ADC评论
October 27, 2022
On October 26, AstraZeneca announced that the Phase III CAPItello-291 study of its Akt1/2/3 inhibitor capivasertib in combination with fulvestrant in breast cancer patients met
Pfizer’s COVID-19 mRNA vaccine to quadruple price
ADC评论
October 26, 2022
With uptake slow in the United States for COVID-19 booster shots that the government supplies for free, what will a 400% price increase do to
Two patients died, CD28/PD-L1/CTLA-4 triple immunotherapy clinical trial terminated
ADC评论
October 26, 2022
On October 24, Alpine Immune Sciences announced that it had terminated two clinical trials of the conditional CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor davoceticept
Daiichi Sankyo’s new drug for the treatment of AML receives FDA priority channel
ADC评论
October 25, 2022
On October 24, the Japanese pharmaceutical company Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA)
Tricida Phase III VALOR-CKD clinical failure, share price plummets 94%
ADC评论
October 25, 2022
On October 24, Tricida announced key results from the Phase III VALOR-CKD clinical trial, which was designed to evaluate the ability of veverimer to slow
